Innovative Industry Payer Agreements Roundtable

Innovative Industry Payer Agreements: Key People

Biographies

Ambrose Carrejo, PharmD
National Pharmaceutical Contracting Leader, Kaiser Foundation Hospitals

Dr. Ambrose Carrejo received his Doctor of Pharmacy degree from the University of California at San Francisco's School of Pharmacy in 1986. He completed his clinical residency at Long Beach Memorial Hospital in June of 1987. With the schooling and residency completed, he began his professional career at the Pacific Presbyterian Medical Center in San Francisco, California. There he worked as a clinical pharmacist running the Total Parenteral Nutrition Service for pharmacy and also providing clinical services to the medical/surgical ward. He left this position in February of 1990 to begin working for Kaiser Foundation Hospitals.

He began his career with Kaiser as a Drug Education Coordinator (DEC) at Kaiser Richmond, and was soon also given responsibility for Kaiser Oakland Medical Center. He was then promoted to Clinical Operations Manager where he had oversight of the drug use management efforts and the ambulatory clinic pharmacists. In June of 1999 Ambrose was promoted to Drug Use Manager for Northern California. In this role he provided oversight and leadership for the Drug Education Coordinators of Northern California. In June of 2006, Dr. Carrejo was promoted to Assistant Director of Pharmaceutical Contracting. Finally in May, 2008 he was promoted to his current position: National Pharmaceutical Contracting Leader, where he is responsible for the contracting of all pharmaceutical purchases for the entire Kaiser Permanente program.

During his career he has testified before the U.S. Senate and provided background information to government agencies and private counsel on matters regarding the purchase and marketing of pharmaceuticals. He has also provided testimony in several trials for the prosecution.

Brian Cuffel, PhD
Senior Director, Global Market Access, Pfizer Inc.

Dr. Brian Cuffel, is Senior Director in the Market Access group of Pfizer's Primary Care Business Unit. He leads the Regional Health Economics and Outcomes Research functions in the US and EUCAN regions. He joined Pfizer in 2004 as Director of US Outcomes Research following 15 years evaluating health care system innovations in managed care, disease management, and academic medicine. He has published extensively throughout his career, performed peer-reviews across a range of medical journals, and acted on AHRQ and SAMHSA grant review panels.

Lou Garrison, PhD
Professor, Pharmaceutical Outcomes Research & Policy Program, Department of Pharmacy, and Adjunct Professor, Departments of Global Health and Health Services, University of Washington

Dr. Lou Garrison is Professor in the Pharmaceutical Outcomes Research & Policy Program in the Department of Pharmacy and Adjunct Professor in the Departments of Global Health and Health Services at the University of Washington, where he joined the faculty in 2004. For the previous 12 years, Dr. Garrison worked as an economist in the pharmaceutical industry. Most recently, he was Vice President and Head of Health Economics & Strategic Pricing in Roche Pharmaceuticals, and was based in Basel, Switzerland, in 2002-4. He oversaw the development of the economic and pricing strategies, and research plans for all Roche compounds. Prior to this, he was Director of the Project HOPE Center for Health Affairs. In eight years there, he worked on a wide variety of health policy issues, including studies of health care reform both in the U.S. and overseas. Before this, he worked at the Battelle Human Affairs Research Centers in Seattle, where he carried out studies of the adequacy of physician manpower supply and the cost-effectiveness of kidney and heart transplantation.

Dr. Garrison received a BA in economics from Indiana University, and a PhD in economics from Stanford University. Dr. Garrison's research interests include national and international health policy issues related to pharmacogenomics and personalized medicine; regulatory risk-benefit analysis; insurance, pricing, reimbursement, and risk-sharing agreements; as well as the economic evaluation of pharmaceuticals, diagnostics, devices, surgical procedures, and vaccines, particularly as related to organ transplantation, renal disease, influenza, measles, and cancer. From 2007-2009, he served on the Board of Directors of the International Society for Pharmacoeconomics and Outcomes Research.

Judith Glennie, PharmD, MSc, FCSHP 
Director, Strategic Health Technology Assessment (HTA), Janssen Inc.

Judith Glennie is a senior member of the health care community with over 25 years of experience in pharmaceutical policy, education, research, consulting and practice. Her professional experience is diverse with involvement at local, provincial, national and international levels.

Her leadership roles have included the creation of systems for evidence-based drug evaluation, rational drug use, and policy development founded in economic and clinical outcomes evaluation and research. Dr. Glennie's educational background includes a Bachelor of Science in Pharmacy from the University of Toronto; a Doctorate in Clinical Pharmacy from Wayne State University (Detroit); a Master of Science in Community Health Science from the Faculty of Medicine at the University of Manitoba; and induction as a Fellow of the Canadian Society of Hospital Pharmacists.

Judy was called to public service via a Federal Cabinet appointment to the Patented Medicine Prices Review Board (PMPRB) from 1995 to 1999. She has served in a variety of other capacities in public sector branches, including the Ontario Ministry of Health and Long-Term Care - Drug Programs Branch, and Health Canada's Health Products and Foods Branch, where she worked with the Therapeutic Products Directorate and Assistant Deputy Minister's Office. Judy joined the private sector in 2007 and is currently Director - Strategic Health Technology Assessment (HTA) for Janssen Inc. (Canada). Dr. Glennie sits on the Board of Directors of the Drug Information Association (DIA), a non-profit, international professional development and networking organization whose more than 18,000 members are involved in all aspects of the discovery, development, regulation, surveillance, and marketing of therapeutic products. She serves as the chair of the Board Compensation Committee, chair of the Board Policy and Education Subcommittee of the Governance and Leadership Committee, and Co-Chair of the DIA Real-World Outcomes Task Force.

Edward Godber 
Head, European Union Access to Medicines, GlaxoSmithKline

Chris Henshall 
Chair, HTAi Policy Forum, Health Technology Assessment International

Dr. Chris Henshall works as an independent consultant, advising governments, public and private sector organizations on health, research and innovation policy. He was the Founding President of Health Technology Assessment International (HTAi) and is currently Chair of the HTAi Policy Forum and a Board member of the Alberta Research and Innovation Authority, an Associate Professor in the Health Economics Research Group at Brunel University, and an honorary Fellow in the Centre for Health Economics at the University of York.

Chris has worked previously for the Health Promotion Research Trust, the UK Medical Research Council, the Department of Health and NHS in England (where he was involved in establishing the NHS R&D Budget, the NHS HTA Programme and the National Institute for Health and Clinical Excellence), the Department of Trade and Industry (where he was responsible for UK science and innovation policy and funding), and the University of York (where he was responsible for promoting enterprise and innovation and links with the economy, government and businesses at home and overseas).

Don Husereau 
Independent Consultant; Former Senior Advisor, Canadian Agency for Drugs and Technologies in Health (CADTH)

Don Husereau is a former Senior Advisor for the Canadian Agency for Drugs and Technologies in Health (CADTH). He received both his BSc in Pharmacy (1993) and his MSc (2000) from the University of Alberta's faculty of Pharmacy and Pharmaceutical Sciences. He joined CADTH in 2001 and, since then, has contributed to the development of several programs including an Environmental Scanning program, and a Rapid Review service.

At CADTH, Don initiated the Health Technology Analysis Exchange, a network of Canadian Health Technology Assessment producers, who coordinate the gathering of evidence and policy advice regarding health technologies to support the needs of the Canadian Federal, Provincial, and Territorial health jurisdictions. Don has also developed CADTH's coordinated national process for identification, refinement, prioritization, and assignment of policy research. In 2005, he led the completion of the 3rd edition of the CADTH Health Technology Assessment (HTA) Guidelines for the Economic Evaluation of Health Technologies: Canada.

He is an editorial advisor for Value in Health and an academic editor for the Public Library of Science ONE journal, as well as a reviewer for the Cochrane Hypertension Review Group and Mediadoctor.ca. Don's specific interests are scientific epistemology and judgment and decision-making and their application to health economics and policy decisions.

Olaf Koester, MBA, RPh
Drug Plan Director, Drug Management Policy Unit, Manitoba Health

Olaf Koester is Director, Drug Management Policy Unit, Provincial Programs and Services with Manitoba Health. He advises government, including the Minister of Health, on all aspects of drug and ancillary benefit program design and management, provincial policies, directives and legislation.

Mr. Koester has extensive leadership experience in strategic and operations management, administrative management, public policy and program development, supply chain and drug use management and management consulting. He maintains an active pharmacy practice in the community, acute and long-term care sectors. He also serves as Advisor to Queen's and Queen's/Cornell MBA students enrolled in the Management Consulting, New Ventures Project, and Global Business Venture courses. He served for more than four years as co-chair of the interim Joint Oncology Drug Review process steering committee, which was the precursor to pCODR. Mr. Koester holds bachelor degrees in both Microbiology and Pharmacy from the University of Manitoba, an MBA from Queen's University in Kingston, Ontario, and post-graduate health research education certificates from the Harvard Public School of Health.

Kevin Leshuk 
General Manager, Celgene Inc.

Kevin Leshuk began his career in the pharmaceutical/biotech industry in the early 1990's with Adria Oncology. He is presently the Canadian General Manager for Celgene, a multinational biopharmaceutical company focused on the discovery, development and commercialization of products for the treatment of cancer and other severe, immune-inflammatory conditions. Through his career, Kevin has had the tremendous good fortune to work within some of the leading Canadian pharmaceutical companies that have provided the opportunity to work in multiple therapeutic areas. Over the past 20 years, Kevin has held management and senior management roles with specific responsibilities in Sales, Marketing, Key Account Management and most recently Market Access.

Alison Maloney, MFSc, MBA
Director, Regulatory Affairs, AstraZeneca Canada Inc.

Alison Maloney, MFSc, MBA, is the Director of Health Economics and Reimbursement at AstraZeneca Canada Inc. Prior to this, Alison was the Director of Regulatory Affairs for AstraZeneca. Throughout these years she has been a member of both Rx&D on the Regulatory Affairs Committee and Federal, Provincial and Territorial Subcommittee and BIOTECanada with the Health Advisory Board. Alison is also actively involved with the Canadian Association of Professional Regulatory Affairs (CAPRA), a not-for-profit organization. Within CAPRA she has held the role of Treasurer and is currently the Chairman. Alison's formal education includes a Master in Forensic Science from George Washington University and a Master in Business Administration from the Schulich School of Business.

Newell McElwee 
Executive Director, U.S. Outcomes Research Group, Merck and Company Inc.

Dr. Newell McElwee is Vice-President of Outcomes Research at Pfizer where he leads a group of scientists focused on health economics, patient-reported outcomes, quality of care, and health disparities. He has worked in the pharmaceutical industry since 1992. His educational background is in pharmacy (BS, University of Louisiana; PharmD, Mercer University) and epidemiology (MSPH, University of Utah). He also completed clinical residency and a research fellowship. One of his key interests is fostering the use of decision sciences to inform real world decisions, including internal investment decisions in industry, technology assessment and adoption, and health policy.

He is a member of a number of several Outcomes related professional societies (SMDM, ISPOR, ISPE) and serves on several academic advisory boards (Duke, University of North Carolina, and University of Washington).

Jorge Mestre-Ferrandiz, PhD
Senior Economist, Office of Health Economics

Dr. Jorge Mestre-Ferrandiz re-joined the Office of Health Economics in February 2006 as a Senior Economist after a year working at Farmaindustria, the Spanish pharmaceutical trade association. Current research interests include medicines' pricing and reimbursement systems across the world, the economics of the pharmaceutical industry, the economics of innovation and incentives to encourage medical research and development.

Before joining Farmaindustria, Jorge was working for the Office of Health Economics. His specific responsibility at the OHE was to conduct research and consultancy projects, in the field of the economics of the pharmaceutical industry. Jorge also provided economic and policy advice to the Association of the British Pharmaceutical Industry. He has presented in various international conferences on pricing and reimbursement of pharmaceuticals.

Jorge is a referee for Health Economics, Journal of Health Economics, International Journal of the Economics and Business, Spanish Journal of Health Economics and Value in Health, plus he is a member of the Editorial Board of the Revista Española de Economia de la Salud (Spanish Journal of Health Economics).

He completed his doctorate thesis "Essays on the Pharmaceutical Industry" at Universidad Autónoma de Barcelona (Spain) in January 2002.

Glenn Monteith 
Assistant Deputy Minister, Health Workforce Division, Alberta Health and Wellness

Glenn Monteith is an economist by training and vocation, and has worked in the health sector for more than 22 years in a variety of roles and locations. Prior to joining the Government of Alberta, Glenn was a Vice President for Health and Pharmaceutical Practices in a private sector firm. He has a wealth of experience in both the private and public sectors across North America in the areas of health policy and pharmaceutical practice, having worked for two large multi-national pharmaceutical and life sciences companies, two health management consulting firms and as a public servant in two other provinces.

Glenn joined Alberta Health and Wellness in 2004, in the role of Executive Director of the Pharmaceuticals and Life Sciences Branch. Since September 2007, Glenn has been Assistant Deputy Minister of the Health Workforce Division at Alberta Health and Wellness. Within his portfolio, he has the Ministry's lead on the following files: labour relations, including the lead on negotiating the Trilateral Master Agreement with the Alberta Medical Association and Alberta Health Services; Workforce Policy and Planning, including workforce research, planning, education, immigration, TILMA, AIT and the Health Professions Act; The Innovative Compensation Branch that manages the Ministry's efforts related to compensation for allied health professionals, Academic and Clinical Alternate Relationship plans for physicians, Primary Health Care, Academic Medicine and the Schedule of Medical Benefits; and The Pharmaceutical Funding and Guidance Branch, which manages the Ministry's publicly funded drug benefit programs.

In addition Glenn is presently the Provincial/Territorial Co-Chair of the Advisory Committee on Health Delivery and Human Resources (ACHDHR) reporting to the Conference of Deputy Ministers of Health.

Bob Nakagawa 
Assistant Deputy Minister of Health, British Columbia Ministry of Health

Bob Nakagawa is the Assistant Deputy Minister of Pharmaceutical Services in the Ministry of Health Services in British Columbia.

Bob received his pharmacy degree from UBC and completed a residency at St Paul's Hospital in Vancouver. He has held leadership positions in regional health authorities, hospitals, government, and the pharmacy profession. This included serving as the President of the College of Pharmacists of BC as well as the Canadian Society of Hospital Pharmacists. He has been instrumental in the development of numerous innovative programs and has received provincial, national and international awards in recognition of his contributions.

Lucie Robitaille 
General Director, Le conseil du medicament, Institut national d'excellence en santé et en services sociaux (INESSS)

BIO IN TRANSLATION

Mel D. Walker, BPharm, MRPharmS, PhD
Senior Director, Value Expert Engagement & Collaboration, GlaxoSmithKline

Dr. Mel Walker's current role was specifically created to help GSK develop a deeper and more focused understanding of payer needs by ensuring that their views are both listened to and acted upon. He has been able to drive greater customer focus at GSK by helping the company to engage with key value experts representing the perspectives of healthcare system stakeholders involved in the appraisal and reimbursement of new medicines. Previously at GSK, he headed the European Oncology Health Outcomes team where his work involved developing insights about how payers value cancer medicines and using these perspectives to support patient access by ensuring that clinical development plans resulted in medicines that were "reimbursable" as well as "approvable."

Following a Pharmacy degree and a doctorate in health outcomes, Mel spent five years at Roche UK where he had health outcomes responsibility for their marketed portfolio. During this time, he co-developed several reimbursement submissions for NICE. Mel has co-authored over 30 research papers and abstracts, as well as two book chapters, and worked in several therapeutic areas including oncology, haematology, osteoporosis, rheumatoid arthritis, nephrology, transplantation, obesity, HIV and Alzheimer's disease. He has chaired a number of international conferences in the areas of market access, the HTA Regulatory interface, conditional reimbursement and risk sharing.

Dr. Walker is also affiliated with the Centre for Socioeconomic Research (University of Wales) and sits on the Steering Committee for the Centre for Innovation in Regulatory Science (formerly CMR International Institute for Regulatory Science).

Shekhar Yerramilli, BSc, MBA
CEO, daVIZta Inc.

Shekhar Yerramilli has over twelve years of experience in Pharmaceutical contracting and pricing compliance. His areas of expertise include Managed Market Strategy, Pricing Analytics, Contract Operations, Government Pricing Compliance, and implementing variety of systems for automating Revenue Management needs. As a trusted advisor to his clients, Shekhar has executed several engagements helping clients optimize their revenue and mitigate their compliance risks through improved analytics, streamlined operations, and controlled automation. Shekhar is the Chief Executive Officer and co-founder of daVIZta, Inc. a premier analytical services firm that specializes in offering a range of solutions to address Pharmaceutical Contracting between manufacturers and healthcare stakeholders.

Prior to starting his firm, Shekhar worked for premier consulting firms such as IMS Consulting, Envision Consulting, and CSC, and before that he worked for Citibank. Shekhar has an MBA in Marketing and BSc in Engineering.